Tags : TJ202/MOR202

$I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma$

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients

Vartika Singh January 6, 2020

Shots: The first P-II NCT03860038 trial involves assessing of TJ202/MOR202 as a 3L treatment in patients with R/R MM while the second P-II trial assess TJ202/MOR202 + lenalidomide (LEN) + […]readmore

Tags : TJ202/MOR202

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : TJ202/MOR202

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company